BIRC5 and colonic neoplasm: Results of the real-time PCR showed that inhibition of PODXL-downregulated TAZ downstream targets including AXL, CTGF, CYR61, Survivin, and CyclinD1 (Figure 2B), confirming the association between PODXL and the TAZ signature in colon cancer patients.